Walkers (Hong Kong) Acts on Ascletis Pharma Inc. IPO

Walkers is delighted to have acted as Cayman Islands counsel to Ascletis Pharma Inc. ("Ascletis") on its listing on the Main Board of the Hong Kong Stock Exchange. Ascletis is the first successful Hong Kong listing under new rules of Chapter 18A designed to attract early-stage biotech firms.

Ascletis, a Chinese biotechnology firm based in Hangzhou, focuses on developing and commercialising drugs for combatting HIV, the hepatitis B virus ("HBV") and the hepatitis C virus ("HCV"). Ascletis currently has two HCV drug candidates at-or-near the commercial-stage, one HIV drug candidate that has completed a phase IIa clinical trial, and one liver cancer drug candidate that has completed phase I and phase I extension clinical trials.

The Walkers team was led by Hong Kong partner Yin Xu with assistance from counsel Jo Lit.


In addition to Ascletis, Walkers is currently advising other biotechnology companies on Chapter 18A and the merits of a Hong Kong Stock Exchange IPO. 

Jo LitPartnerT +852 2596 3383jo.lit@walkersglobal.com